Journey of Voyager’s ALS gene therapy to clinic hindered by need to find alternative payload
Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis (ALS) candidate into the clinic in the coming months as the gene therapy company looks to rejig the asset’s payload.
Voyager Therapeutics no longer expects to take its amyotrophic lateral sclerosis (ALS) candidate into the clinic in the coming months as the gene therapy company looks to rejig the asset’s payload.
